budesonide

Type: Keyphrase
Name: budesonide
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

TEVA PHARMACEUTICAL : Announces UK High Court Gives Positive Judgment in the Company's Patent Case Against AstraZeneca

By a News Reporter-Staff News Editor at Health & Medicine Week -- Teva Pharmaceutical Industries Ltd. , (NYSE:TEVA) announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity ... [Published 4 Traders - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Teva Thwarts UK Patent Challenge Against AZ’s Symbicor

Teva is clear to market its version of AstraZeneca’s chronic obstructive pulmonary disorder drug Symbicort in the United Kingdom, after the High Court there struck down an AZ indication patent on grounds of obviousness.The EP ’877 patent covered the ... [Published FDA News - Sep 09 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Teva Wins Patent Litigation vs. AstraZeneca in UK

Teva Pharmaceutical Industries Ltd. ( TEVA - Analyst Report ) received a favorable ruling from the UK High Court in a patent infringement case related to its generic version of AstraZeneca’s ( AZN - Analyst Report ) Symbicort (fixed dose combination ... [Published Zacks.com - Sep 04 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Teva launches DuoResp Spiromax inhaler in UK

:40 in Consumer Healthcare News Teva has announced the UK launch of its new DuoResp Spiromax inhaler, intended for adult patients with asthma or chronic obstructive pulmonary disease (COPD). The budesonide/formoterol therapy is intended for patients aged ... [Published Zenopa - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 2 reports

UK launch for Teva's COPD/asthma inhaler

A new therapy for asthma and chronic obstructive pulmonary disorder has hit UK shores after Teva launched its new inhaler DueResp Spiromax (budesonide/formoterol).The inhaler holds a license to treat patients aged 18 or over suffering from these conditions ... [Published Pharmacy Magazine - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Short-term antiinflammatory treatment may reduce airway hyperresponsiveness

medwireNews: Short-term treatment with budesonide and montelukast may decrease airway hyperresponsiveness to exercise and mannitol challenge in children and adolescents with exercise-induced bronchoconstriction, Swiss study data show.The study included ... [Published MedWire News - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 9 reports

Teva Receives Positive Judgment From UK Court Against AstraZeneca

Teva has won its case against AstraZeneca in a UK court over the validity of Teva's use of the latter's patent for SMART (Single Inhaler Maintenance and Reliever Therapy)Page 1 of 2Click Ticker to See live coverageTeva Pharmaceuticals Industries Ltd. ... [Published Bidness Etc - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 2 reports

UK court backs Teva in patent case over AstraZeneca's Symbicort

Teva said Wednesday that the UK High Court determined that AstraZeneca's patent covering the SMART indication of Symbicort (formoterol/budesonide) was obvious and rejected the latter's proposed amendments to the patent on the basis that they added matter. ... [Published FirstWord Pharma - Sep 03 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 2 reports

Inhaled medications: Nefarious reasons for the lack of competition

Check out the prices for nebulizer solutions of albuterol and budesonide ( generic Pulmicort). They are totally affordable. $4 for a month for albuterol. $14 for a month for budesonide respules. Pulmicort respules used to be very expensive. Now even the ... [Published BioPortfolio - Aug 29 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Three UC drugs approved by FDA

As a disease with both chronic and acute manifestations, ulcerative colitis often requires a balancing act of maintenance and rescue therapies. While management of this condition is often a lifelong endeavor, severe, acute episodes also may occur, requiring ... [Published Orthopedics Today - Aug 25 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

BUDESONIDE Capsule [Carilion Materials Management]

Entities: budesonide
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

BUDESONIDE Suspension [Teva Pharmaceuticals USA Inc]

Quotes

...treatment to the patient in a device that is intuitive and easy to use," said Rob Koremans, MD, President and CEO, Teva Global Specialty Medicines. "Yesterday's judgment is a big step in enabling us to make a difference to people's lives in the UK and all across Europe ."
...Dr Kevin Gruffydd-Jones, GP principal at the Box Surgery in Wiltshire, said: "The intuitive Spiromax inhaler device aids simpler inhaler technique. This in turn has the potential to improve asthma and COPD management and control." This comes after the firm launched generic eplerenone tablets last month for treating patients who have suffered a heart attack
Supplementing the background information on this patent, NewsRx reporters also obtained the inventors' summary information for this patent: "According to the present invention, methods for spray drying hydrophobic drugs and other materials are provided which overcome at least some of the deficiencies noted above with respect to prior spray drying processes. In particular, the spray drying methods of the present invention permit the simultaneous spray drying of the hydrophobic component with a hydrophilic component, such as a hydrophilic pharmaceutical excipient, under conditions which result in a dry powder comprising mixtures of both the hydrophilic and hydrophobic components. Although the methods of the present invention are particularly useful for forming pharmaceutical compositions where the hydrophobic component is a hydrophobic drug, usually present at from 0.01% to 95% of the powder, and the hydrophilic component is a hydrophilic excipient, usually present at from 99.99% to 5% of the powder, the methods may be applied more broadly to form dry powders comprising a variety of hydrophobic and hydrophilic components at different concentration ranges, including hydrophilic drugs and hydrophobic excipients."

More Content

All (86) | News (54) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Teva Pharmaceutical Is Poised To Grow [Published Seeking Alpha - Sep 14 2014]
Vectura Group Following A Familiar Path [Published Seeking Alpha - Sep 13 2014]
Global Glomerulonephritis Therapeutics Pipeline... [Published Individual.com - Sep 12 2014]
TEVA PHARMACEUTICAL : Announces UK High Court G... [Published 4 Traders - Sep 10 2014]
Teva receives favorable ruling in patent case a... [Published Individual.com - Sep 10 2014]
Teva Thwarts UK Patent Challenge Against AZ’s S... [Published FDA News - Sep 09 2014]
Encouraging new data with AstraZeneca’s benrali... [Published Pharma Letter - Sep 08 2014]
Utilization of Inhaled Corticosteroids for Infa... [Published Plosone.org - Sep 05 2014]
Teva Wins Patent Litigation vs. AstraZeneca in UK [Published Zacks.com - Sep 04 2014]
Teva launches DuoResp Spiromax inhaler in UK [Published Zenopa - Sep 04 2014]
Aereo, Teva-AstraZeneca, Cartoon Parody: Intell... [Published Bloomberg - Sep 04 2014]
Short-term antiinflammatory treatment may reduc... [Published MedWire News - Sep 03 2014]
Teva Receives Positive Judgment From UK Court A... [Published Bidness Etc - Sep 03 2014]
UK launch for Teva's COPD/asthma inhaler [Published Pharmacy Magazine - Sep 03 2014]
UPDATE 1-UK court backs Teva rival to AstraZene... [Published London South East - Sep 03 2014]
UK court backs Teva in patent case over AstraZe... [Published FirstWord Pharma - Sep 03 2014]
UK court backs Teva rival to AstraZeneca lung drug [Published London South East - Sep 03 2014]
Teva Announces UK High Court Gives Positive Jud... [Published Benzinga.com - Sep 03 2014]
English High Court backs Teva on AstraZeneca in... [Published Globes - Sep 03 2014]
UK launch for Teva's COPD/asthma inhaler [Published Pharma Times - Sep 03 2014]
Teva: UK High Court Gives Positive Judgment In ... [Published RTTNews.com - Sep 03 2014]
UK High Court Rules In Favor Of Teva In AstraZe... [Published RTTNews.com - Sep 03 2014]
Teva Announces UK High Court Gives Positive Jud... [Published InvestorPoint.com - Sep 03 2014]
Teva Announces UK High Court Gives Positive Jud... [Published Business Wire Professional Services News - Sep 03 2014]
Teva Announces UK High Court Gives Positive Jud... [Published Business Wire Health News - Sep 03 2014]
Morphine polymer release system [Published PharmCast - Sep 03 2014]
Food Allergy Testing in Eosinophilic Esophagitis [Published Diabetes Care - Sep 01 2014]
Inhaled medications: Nefarious reasons for the ... [Published BioPortfolio - Aug 29 2014]
Inhaled medications: Nefarious reasons for the ... [Published KevinMD.com - Aug 29 2014]
Pediapharm Announces First Quarter Financial Re... [Published BusinessWeek - Aug 28 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Teva Announces UK High Court Gives Positive Jud... [Published Business Wire Professional Services News - Sep 03 2014]
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the ...
Teva Announces UK High Court Gives Positive Jud... [Published Business Wire Health News - Sep 03 2014]
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the ...
Inhaled medications: Nefarious reasons for the ... [Published KevinMD.com - Aug 29 2014]
Check out the prices for nebulizer solutions of albuterol and budesonide (generic Pulmicort). They are totally affordable. $4 for a month for albuterol. $14 for a month for budesonide respules. Pulmicort respules used to be very expensive. Now even the ...
BUDESONIDE Capsule [Carilion Materials Management] [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 20, 2014 EST ...
BUDESONIDE Suspension [Teva Pharmaceuticals USA... [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 19, 2014 EST ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Orion receives first marketing authorisations f... [Published GlobeNewswire: Advertising News - Apr 14 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.